Диссертация (1139560), страница 45
Текст из файла (страница 45)
A., & Smith, J. J. The Relation of Blood Cholesterol and theSize of Prostatic and Vesicular Transplants in the Anterior Chamber of theEye. The Journal of Experimental Medicine. 1937, 66(3), 291–296.313176. Morganti P, Fabrizi G, James B, Bruno C. 1998. Effect of gelatin-cystineand Serenoa repens extract on free radicals level and hair growth. J ApplCosmetol 16:57-64177. Mottet N. (Chair), Bellmunt J., Briers E.
(Patient Representative), BollaM., Bourke L., Cornford P. (Vice-chair), De Santis M., Henry A.M., JoniauS., Lam T.B., Mason M.D., van der Poel H.G., van der Kwast T.H., RouvièreO., Wiegel T. Guidelines Associates: N. Arfi, R.C.N.. van den Bergh, T. vanden Broeck, M. Cumberbatch, N. Fossati, T. Gross, M. Lardas, M. Liew, P.Moldovan, I.G. Schoots, P.M. Willemse.
Guidelines on Prostate Cancer.EAE-ESTRO-ESUR-SIOG, 2017178. Mowschenson P.M., Hodin R.A. Outpatient thyroid and parathyroidsurgery: a prospective study of feasibility, safety, and costs. Surgery, 1995,Dec;118(6):1051-3; discussion 1053-4.179.
Mullins C, Lucia MS, Hayward SW, et al. A comprehensive approachtoward novel serum biomarkers for benign prostatic hyperplasia: the MPSAConsortium. J Urol 2008;179:1243–56.180. Murakoshi M, Tagawa M, Inada R, Suzuki M. Effects of testosterone, andtestosteroneplusestrogen,inthecastratedrat ventral prostate:Histopathological and immunocytochemical studies.
Tokai J Exp Clin Med1992; 17: 133.181. Nickel J. C., Roehrborn C. G., O'Leary M. P., Bostwick D. G., SomervilleM. C., Rittmaster R. S. The relationship between prostate inflammation andlower urinary tract symptoms: examination of baseline data from theREDUCE trial // Eur Urol. 2008. T. 54, № 6. C. 1379-84.182. Nickel JC, Downey J, Young I, Boag S. Asymptomatic inflammationand/or infection in benign prostatic hyperplasia. BJU Int 1999;84:976–81.183.Nickel JC, Roehrborn CG, O’Leary MP, Bostwick DG, Somerville MC,Rittmaster RS. The relationship between prostate inflammation and lowerurinary tract symptoms: examination of baseline data from the REDUCE trial.Eur Urol.
2008 Dec;54(6):1379-84.314184. Nickel JC. Placebo therapy of benign prostatic hyperplasia: a 25-monthstudy. Canadian PROSPECT Study Group. Br J Urol. 1998 Mar;81(3):3837. PubMed PMID: 9523656.185. Oelke M, Madersbacher S. Primary and secondary prevention of benignprostatic hyperplasia: current knowledge and implications for clinicalmanagement.UrologeA.2011Oct;50(10):1257-8,1260-4.doi:10.1007/s00120-011-2618-3. Review. German. PubMed PMID: 21901570.186. Ordway R.
W., Singer J. J. and Walsh V. (1991) Direct regulation of ionchannels by fatty acids. Trends Neurosci. 14, 96-100.187. Palacios P, Gutkind G, Rondina RV, de Torres R, Coussio JD. 1983. GenusBaccharis. II. Antimicrobial activity of B. crispa and B. notosergila. PlantaMed 49:128.188. Paubert-Braquet M, Mencia Huerta JM, Cousse H, Braquet P. Effect of thelipidic lipidosterolic extract of Serenoa repens (Permixon) on the ionophoreA23187-stimulated production of leukotriene B4 (LTB4) from humanpolymorphonuclear neutrophils.
Prostaglandins Leukot Essent Fatty Acids.1997 Sep;57(3):299-304. PubMed PMID: 9384520.189. Paubert-Braquet M, Ranaud J, and Braquet P. 1997. Permixon® [lipidsterolic extract of Serenoa repens (LSESr)] and some of its componentsinhibits b-FGF- and EGF-induced proliferation of human prostate organotypiccell lines.
J Urol 157(Supplement):138(A541). Abstract.190. Paubert-Braquet M., H.Cousseb, J.-P. Raynaudc, J.M. Mencia-Huertaa,P.Braquet. Effect of the lipidosterolic extract of Serenoa repens (Permixon) andits major components on basic fibroblast growth factor-induced proliferation//Eur Urol 1998;33:340-347191. Payan D. G., Goetzl E. J.
Specific suppression of human T lymphocytefunction by leukotriene B4. J Immunol 1983; 131:551-553.192. Pinn G. Herbal medicine in renal and genitourinary disease. 2001. AustFam Physician 30:974-977.315193. Pradhan BK, Chandra K. Morphology of nodular hyperplasia prostate. JUrol 1975; 113: 210.194. Pytel YA, Vinarov A, Lopatkin N, Sivkov A, Gorilovsky L, Raynaud JP.Long-term clinical and biologic effects of the lipidosterolic extract of Serenoarepens in patients with symptomatic benign prostatic hyperplasia. Adv Ther.2002 Nov-Dec;19(6):297-306.195. Qin GD, Xiao MZ, Zhou YD, et al.
Tamsulosin alters levofloxacinpharmacokinetics in prostates derived from rats with acute bacterialprostatitis. Asian Journal of Andrology. 2013;15(2):254-260.196. Rhodes T, Girman CJ, Jacobsen DJ, Roberts RO, Lieber MM, JacobsenSJ. Longitudinal prostate volume in a community-based sample: 7 yearfollowup in the Olmsted County Study of urinary symptoms and health statusamong men. J Urol 2000; 163 (suppl 4): 249. [abstract 1105].197.
Robaire B, Ewing LL, Irby DC, Desjardins C. Interactions of testosteroneand 17-ß estradiol on the reproductive tract of the male rat. Biol Reprod 1979;21: 455.198. Robert G, Descazeaud A, Nicolaïew N, Terry S, Sirab N, Vacherot F,Maillé P, Allory Y, de la Taille A. Inflammation in benign prostatichyperplasia: a 282 patients' immunohistochemical analysis. Prostate. 2009Dec 1;69(16):1774-80.
doi: 10.1002/pros.21027. PubMed PMID: 19670242;PubMed Central PMCID: PMC2833181.199. Robinette CL, Trempus CS, Onks DL. A prolactin-like transcript isexpressed by some of the lymphocytes found in a prolactin-inducedinflammatory process in the rat lateral prostate. Meeting of the federation ofAmerican societies for experimental biology, New Orleans, Louisiana, USA,FASEB (3-4). 1993. A20.200. Robinette CL. Sex hormone induced inflammation and fibromusculargrowth in the rat lateral prostate. Fed Proc 1987; 46: 525.201. Robinette CL. Sex-hormone-induced inflammation and fibromuscularproliferation in the rat lateral prostate.
Prostate. 1988;12:271–286.316202. Roehrborn CG, Siami P, Barkin J, Damião R, Major-Walker K, Morrill B,Montorsi F; CombAT Study Group. The effects of dutasteride, tamsulosin andcombination therapy on lower urinary tract symptoms in men with benignprostatic hyperplasia and prostatic enlargement: 2-year results from theCombAT study.
J Urol. 2008 Feb;179(2):616-21203. Roehrborn CG, Boyle P, Bergner D, Gray T, Gittelman M, Shown T,Melman A, Bracken RB, deVere White R, Taylor A, Wang D, WaldstreicherJ. Serum prostate-specific antigen and prostate volume predict long-termchanges in symptoms and flow rate: results of a four-year, randomized trialcomparing finasteride versus placebo. PLESS Study Group.
Urology 1999;54: 662-669.204. Roehrborn CG, Kaplan SA, Noble WD, et al. The impact of acute orchronic inflammation in baseline biopsy on the risk of clinical progression ofBPH: results from the MTOPS study. J Urol 2005;173(Suppl):346, abstract1277.205. Roehrborn CG, Oyarzabal Perez I, Roos EP, Calomfirescu N, BrothertonB, Wang F, Palacios JM, Vasylyev A, Manyak MJ. Efficacy and safety of afixed-dose combination of dutasteride and tamsulosin treatment (Duodart®)compared with watchful waiting with initiation of tamsulosin therapy ifsymptoms do not improve, both provided with lifestyle advice, in themanagement of treatment-naïve men with moderately symptomatic benignprostatic hyperplasia: 2-year CONDUCT study results.
BJU Int. 2015Sep;116(3):450-9206. Roehrborn CG, Siami P, Barkin J, et al. The influence of baselineparameters on changes in international prostate symptom score withdutasteride, tamsulosin, and combination therapy among men withsymptomatic benign prostatic hyperplasia and an enlarged prostate: 2-yeardata from the CombAT study. Eur Urol. 2009 Feb;55(2):461-71207. Roehrborn C.G., Barkin J., Siami P., Tubaro A., Wilson T.H., Morrill B.B.,Gagnier R.P. Clinical outcomes after combined therapy with dutasteride plus317tamsulosin or either monotherapy in men with benign prostatic hyperplasia(BPH) by baseline characteristics: 4-year results from the randomized,double-blind Combination of Avodart and Tamsulosin (CombAT) trial. BJUInt.
2011;107(6):946−54.208. Roehrborn CG, Siami P, Barkin J, et al. The effects of combination therapywith dutasteride and tamsulosin on clinical outcomes in men withsymptomatic benign prostatic hyperplasia: 4-year results from the CombATstudy. Eur Urol 2010;57:123-31209. Roehrborn CG. Evaluation of the clinicalbenefit of permixon andtamsulosin in severe BPH patients-PERMAL study subset analysis. Eur Urol.2004 Jun;45(6):773-9; discussion 779-80.210.
Rola-Pleszczynski M., Bouvrette L, Gingras D., Girard M. Identificationof interferon-gamma as the lymphokine that mediates leukotriene B4-inducedimmunoregulation. J Immunol 1987; 139:513-517.211. Ruffolo R. R. and Hieble J. P. a-Adrenoceptors. 1994. Pharmac. Ther.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
